1981
DOI: 10.1007/bf00554669
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics and bioavailability of tranexamic acid

Abstract: Tranexamic acid 1 g was given intravenously to three healthy volunteers. Plasma concentrations decayed in three monoexponential phases. Most elimination took place during the first eight hours, giving an apparent elimination half-life of approximately two hours. Plasma clearance ranged between 110-116 ml/min. The urinary recovery of tranexamic acid exceeded 95% of the dose. Ten healthy volunteers were given tranexamic acid 2 g orally on an empty stomach, and together with a meal. Food had no influence on the a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
144
1
2

Year Published

1996
1996
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 227 publications
(157 citation statements)
references
References 12 publications
7
144
1
2
Order By: Relevance
“…This analysis yielded a plasma concentration of approximately 0.2 mg/l TA, roughly 16 hours after the last dose of drug. This is similar to levels observed at this time after administration of a therapeutic dose of TA in humans (Eriksson et al, 1974;Pilbrant et al, 1981).…”
Section: Resultssupporting
confidence: 86%
See 1 more Smart Citation
“…This analysis yielded a plasma concentration of approximately 0.2 mg/l TA, roughly 16 hours after the last dose of drug. This is similar to levels observed at this time after administration of a therapeutic dose of TA in humans (Eriksson et al, 1974;Pilbrant et al, 1981).…”
Section: Resultssupporting
confidence: 86%
“…Thus, one mechanism whereby TA treatment could reduce ANIT-induced liver injury is by inhibiting plasmin-mediated fibrinolysis, thereby stabilizing hepatic fibrin deposits. Our results indicate that plasma TA levels in TA-treated mice sufficiently prolonged clot lysis ex vivo, consistent with inhibition of plasmin, and were similar to those observed in TA-treated humans (Eriksson et al, 1974;Pilbrant et al, 1981). Although TA treatment probably sustained hepatic fibrin deposition in ANIT-treated mice, we were unable to detect a significant increase in hepatic fibrin deposition in ANIT-treated mice given TA.…”
Section: Discussionsupporting
confidence: 80%
“…maintain a therapeutically effective concentration between 5 mg/ dl. Though 30% of the intravenous dose of 10 mg/kg of TXA was detected in the urine during the first hour after administration and the total excretion rose to 45% after 3 hours, approximately 55% remains in circulation upto 24 hours [29]. Therefore maxillofacial trauma surgery does not require a continuous infusion since post operative haemorrhage is of lesser concern than management of immediate haemorrhage in order to clear the airway.…”
Section: Intraoperative Proceduresmentioning
confidence: 99%
“…The plasma levels of TA in five patients collected at 0.5 h after dosing were in the range of 327-497 mM. Plasma levels of 515-547 mM were reported [18] 5 min after intravenous bolus of 1000 mg TA. The proposed method seems simple for monitoring TA in plasma since HPLC analysis of TA in blood usually needs complicate procedures [19,20].…”
Section: Applicationmentioning
confidence: 93%